Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascu…
An institutional-grade, numbers-driven thesis on JNJ — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Johnson & Johnson (JNJ) 65/100 with a 12-month base-case forecast of $282.08 — +9.8% versus the current price of $256.98. Johnson & Johnson trades at $256.98 in the Healthcare sector, with a market capitalisation of $619.30B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for JNJ is $282.08, implying +9.8% versus the current price. The model's 12-month scenario range runs from $337.23 (bear) to $386.03 (bull), with a base case of $350.76.
On the fundamentals, Johnson & Johnson shows a P/E of 29.7, trailing revenue of $94.19B, revenue growth of +6.0% YoY, a dividend yield of 2.04%. This page also tracks JNJ's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
JNJ currently carries a TradersQuant composite score of 65/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $282.08 implies +9.8% from $256.98. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for JNJ is $282.08, about +9.8% versus the latest price of $256.98. Consensus is based on 40 analysts.
TradersQuant's 12-month model forecast for JNJ is a base case of $350.76, ranging from $337.23 (bear) to $386.03 (bull), an expected return of +36.5%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for JNJ over the next 12 months is $350.76 in the base case (bear $337.23, bull $386.03), versus today's price of $256.98. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for JNJ — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates JNJ's fair value at $282.08, implying +9.8% of expected upside versus the current price.
Yes — Johnson & Johnson pays a dividend yielding 2.04% (about $5.24 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
